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1,4-Dioxane is found in consumer products and is used as a solvent in manufacturing. Studies in rodents
show liver tumors to be consistently reported after chronic oral exposure. However, there were
differences in the reporting of non-neoplastic lesions in the livers of rats and mice. In order to clarify
these differences, a reread of mouse liver slides from the 1978 NCI bioassay on 1,4-dioxane in drinking
water was conducted. This reread clearly identiﬁed dose-related non-neoplastic changes in the liver; spe-
ciﬁcally, a dose-related increase in the hypertrophic response of hepatocytes, followed by necrosis,
inﬂammation and hyperplastic hepatocellular foci. 1,4-Dioxane does not cause point mutations, DNA
repair, or initiation. However, it appears to promote tumors and stimulate DNA synthesis. Using EPA
Guidelines (2005), the weight of the evidence suggests that 1,4-dioxane causes liver tumors in rats
and mice through cytotoxicity followed by regenerative hyperplasia. Speciﬁc key events in this mode
of action are identiﬁed. A Reference Dose (RfD) of 0.05 mg/kg day is proposed to protect against regener-
ative liver hyperplasia based on a benchmark dose (BMD) approach. Based on this RfD, a maximum con-
taminant level goal of 350 lg/L is proposed using a default relative source contribution for water of 20%.
 2014 Elsevier Inc. All rights reserved.1. Introduction
1,4-Dioxane is a contaminant of personal care products and
cosmetics, and is also used as a solvent for organic products, lac-
quers, paints, varnishes, oils, waxes, inks, and animal and vegetable
oils, among other uses (US EPA, 2013). Recent evaluations of 1,4-
dioxane’s toxicity are available and general information on its
physical properties can be obtained from documents developed
by the US EPA (2013), Health Canada (2010), NICNAS (1998) and
the Sapphire Group (2007).
Based on weight of evidence assessments, several regulatory
bodies have concluded that 1,4-dioxane is not a mutagen and that
there is evidence of a threshold dose for the formation of liver
tumors (Health Canada, 2010; NICNAS, 1998). NICNAS, 1998 did
note there are several possible epigenetic mechanisms (including
tumor promotion, cell proliferation, etc.) but inconsistent data
from mechanistic studies do not support a clear mechanism.
Similarly, the US Environmental Protection Agency (US EPA,2013) in its recent review of 1,4-dioxane based on the oral route
of exposure, alluded to several possible modes of action (MOA)
including a regenerative hyperplasia, especially for liver tumors,
but then concluded that the available evidence was inadequate
to establish a mode of action (MOA) by which 1,4-dioxane or a
transient or terminal metabolite induces liver tumors in rats and
mice. EPA’s (2013) conclusion is based, in part, on apparent uncer-
tainty in the toxic moiety for 1,4-dioxane and the apparent lack of
noncancer toxicity data from several mouse bioassays at doses that
evoke tumors, or that otherwise appear to have conﬂicting infor-
mation concerning non-neoplastic lesions in the liver of rodents
exposed orally to 1,4-dioxane. Although there is general agreement
among studies on 1,4-dioxane with regard to neoplastic changes,
there are substantial differences in the reporting of non-neoplastic
lesions in the liver from various repeated exposure studies and
carcinogenesis studies. One study (NCI, 1978) reported no non-
neoplastic lesions in the livers of mice, at least at the high dose,
while other studies reported swelling of the centrilobular
hepatocytes, necrosis, and hyperplasia at comparable or lower
doses (Kano et al., 2008, 2009; Yamazaki et al., 1994). Since these
studies span 3 decades, differences in histologic approaches for
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responsible for the differences noted across the studies.
No epidemiology studies, case reports, or clinical trials exist
that examine potential adverse health effects of 1,4-dioxane fol-
lowing oral or dermal exposure. However, multiple studies exam-
ined the effects of acute inhalation exposure in healthy volunteers
(Yant et al., 1930; Fairley et al., 1934; Wirth and Klimmer, 1936;
Silverman et al. 1946; Young et al., 1977; Ernstgard et al., 2006).
Each of these studies is limited by small sample size and some
exposures were very high (i.e., up to 5500 ppm in Yant et al.,
1930). Although limited by small sample sizes and limited latency
periods, these studies found no increased risk of cancer-related
mortality among workers exposed to 1,4-dioxane, Theiss et al.
(1976) also found no evidence of liver or kidney disease among a
small sample of retired workers. Furthermore, two case reports
show that high acute occupational exposure to 1,4-dioxane can re-
sult in liver, kidney, and central nervous system toxicity (Barber,
1934; Johnstone, 1959). Exposure estimates are not available from
Barber (1934), but Johnstone (1959) reported that the worker was
exposed to 208–650 ppm (mean 470 ppm) for 1 week in addition
to an unknown dermal exposure.
In experimental animals, 1,4-dioxane from oral exposures
caused liver toxicity as evidenced by several histological and/or
biochemical changes (e.g., liver enzyme changes, centrilobular
swelling, and/or necrosis) at all time points as early as 13 weeks
of treatment (Kano et al., 2008), and as nicely summarized by
EPA (2013) in a dose-related manner in both sexes of rats and mice
after both oral and inhalation exposures.1 EPA (2013) also showed
that this liver toxicity and nasal toxicity (e.g., nuclear enlargement;
vacuolar change, and/or squamous cell hyperplasia); precedes tu-
mors in time in both sexes of rats and mice2 with liver histopathol-
ogy preceding tumors in dose in both sexes of rats3 and liver toxicity
as evidenced by biochemistry occurring at doses similar to those that
evoke tumors in either sex of mice.4 Liver toxicity as evidenced by his-
topathology does not consistently appear to either precede tumors in
either sex of mice or necessarily even occur at tumorigenic doses. For
example, liver hyperplasia (evidence of a regenerative cell prolifera-
tion) is not recorded in high dose female mice (NCI, 1978), although
it is shown at 15% in the low dose females. Hepatic cytomegaly and
necrosis was also observed for low dose females and for males from
both exposure groups, although this latter evidence for male mice is
equivocal. Single cell necrosis and hepatocellular hypertrophy were
increased in male and female mice given 4000 ppm and above in
drinking water for 13 weeks (Kano et al., 2008) and hyperplasia
was noted in rats and mice following exposure to 1,4-dioxane in
drinking water for 2 years (Yamazaki et al., 1994). The hyperplasia
originally reported in the Yamazaki et al. study (1994) was later
changed to altered hepatocellular foci including acidophilic, baso-
philic, and clear cell foci based on certain diagnostic criteria (Kano
et al., 2009).
In reviewing this information, the lack of appearance (or consis-
tency) of liver toxicity in mice before tumor occurrence, in terms of
dose, seemed at odds with the appearance of liver toxicity before
tumor occurrence in both rats and mice at all time points, and
the appearance of this toxicity before tumors in dose in rats. For
the NCI study, we suspected that the lack of evidence for non-
neoplastic lesions had more to do with the common practice of1 See EPA (2013) Table 4-2 (p. 32), Table 4-5 (p. 41), Table 4-8 (p. 47), Table 4-9 (p.
48), and Table 4-12 (p. 52).
2 See EPA (2013) Table 4-2 (p. 32), Table 4-16 (p. 58), Table 4-17 (p. 59), and
Table 4-22 (p. 69).
3 Compare EPA (2013) Table 4-5 (p. 41) to its Table 4-6 (p. 42); compare Tables 4-8
& 4-9 (p. 47-48) to Tables 4-10 & 4-11 (p. 50); compare Table 4-20 (p. 64) to Table 4-
21 (p. 65).
4 See EPA (2013) Table 4-25 (p. 85).pathologists at this period of time (1978) to record only the most
severe endpoint within an organ of an experimental animal (e.g.,
a tumor) despite the presence of noncancer toxicity. Our suspicion
was conﬁrmed by McConnell (2011) who stated that a common
practice in the late 1970’s was to identify the most severe end-
point, and speciﬁcally for these bioassays, to identify and score
tumors.
In order to explore these differences in liver histopathology for
mice observed across studies and to better understand the
sequence of events that may have contributed to the MOA of the
observed liver tumors, a blinded reread of the NCI (1978) liver
slides for mice was conducted since this study had no reported
non-neoplastic lesions in the liver at the high dose. Following the
completion of this work, a review of all non-neoplastic lesions in
the liver observed in the repeated exposure studies was conducted.
In addition, a thorough review of genotoxicity studies was con-
ducted which included DNA replication and promotion bioassays
as well as mutation, initiation, and DNA repair studies. Based on
the histopathology data as well as the genotoxicity information,
a hypothesis concerning the MOA was developed, as shown in
Fig. 1, and an MOA analysis was performed.
The EPA (2005) cancer guidelines were utilized to conduct the
MOA analysis. This analysis was then used to conduct a dose
response assessment, which was similar in many respects to that
derived by EPA (2013), but sufﬁciently different in outcome and
direction to warrant additional discussion and review by the scien-
tiﬁc community. In brief, our proposed MOA for liver tumors
accounts for nearly all of the ﬁndings, to the point where other tu-
mor MOAs, such as mutagenicity, can be credibly excluded. This
new information and analysis may be valuable to address the po-
tential environmental risk from oral exposures to 1,4-dioxane,
and speciﬁcally for the development of safe concentrations of this
chemical in drinking water. A similar MOA analysis may be needed
for other tumors evoked by 1,4-dioxane.2. Methods
2.1. National Cancer Institute (NCI) data review
Because terminology and practices for reporting liver lesions
has changed since the time of the NCI study (1978), and because
EPA (2005) is focusing more on an understanding of a chemical’s
Mode of Action (MOA) prior to any determination of its dose re-
sponse, a re-review of the liver slides of mice from the NCI study
(1978) was performed. This reanalysis was performed at the Exper-
imental Pathology Laboratories (EPL), Research Triangle Park, NC
during September through November 2012. The objective of the
slide review was to determine if any non-neoplastic lesions in
the liver were present in an effort to understand the sequence of
events that may have contributed to the MOA of the observed liver
tumors in mice. Another reason for the slide review was because at
the time of the original slide review (i.e., 1978) the NCI typically re-
corded only the most severe diagnosis on a given slide, (e.g., ade-
noma or carcinoma). During this timeframe, the focus of cancer
bioassays was to determine the potential carcinogenic activity of
the chemical, not its potential chronic toxicity. For example, if an
adenoma, carcinoma, and evidence of chronic toxicity (e.g., hepato-
cellular hypertrophy), were all present on a given slide, only the tu-
mor response was typically recorded. Thus, it was unclear whether
non-neoplastic lesions were present in the livers of mice but were
not recorded in the NCI carcinogenicity study. An initial review of
the livers from ﬁve control male mice was conducted followed by
ﬁve male mice from the high dose. The reason for the initial review
was to obtain a baseline for the livers of control animals and to
understand the spectrum of lesions that occurred in the high dose
Fig. 1. Proposed Mode of Action (MOA) approach for 1,4-dioxane liver tumors.
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exposure. The remainder of male mice and female mice from the
carcinogenicity study were examined in a ‘‘blind’’ fashion with
no knowledge of dose. It should be noted that in some cases the li-
ver could not be evaluated for non-neoplastic lesions because not
enough tissue was available due to tumor involvement or postmor-
tem autolysis. In such cases these animals were deleted from the
sample.
Terminology for this reevaluation included:
 Depletion of hepatocellular glycogen – Homogeneous cyto-
plasmwithin a hepatocyte due to the lack of glycogen. Glycogen
appears as ‘‘empty’’ spaces in the cytoplasm of normal
hepatocytes when stained with H&E. Hepatocellular hypertro-
phy – Conspicuously larger than normal hepatocytes due to
an increase in the amount of cytoplasm. Hepatocytes are also
typically more eosinophilic and devoid of recognizable
glycogen. If hypertrophy was present, an attempt was made
to determine if there was a zonal predilection, e.g., periportal,
midzonal, centrilobular or diffuse.
 Necrosis (particularly hepatocellular) – Increased cytoplasmic
eosinophilia and disintegration of cytoplasm and cell mem-
branes. Nuclei are often still apparent.
 Inﬂammation – Focal inﬂux of neutrophils and lymphocytes,
primarily in the area of hepatocellular necrosis.
 Fatty inﬁltration – Individual hepatocytes containing round
clear vacuoles.
 Non-neoplastic hyperplasia (e.g., focal hyperplasia of several
types: Kupffer cell, bile duct, and basophilic, eosinophilic, clear
cell, and mixed cell hyperplastic foci)- Kupffer cell hyperplasia
is typically recognized as diffuse proliferation of Kupffer cells.
Bile duct hyperplasia is similarly recognized as multifocalproliferation of bile ducts. In contrast, basophilic, eosinophilic,
clear-cell and mixed-cell foci are recognized as focal clonal-like
accumulations of normal appearing hepatocytes with tinctorial
qualities that allow for the speciﬁc morphological classiﬁca-
tions. Importantly, the various types of hepatocellular foci are
considered pre-neoplastic changes.
 Various types of neoplasms – Hepatocellular adenoma and car-
cinoma, leukemia, lymphoma, etc. are diagnosed using standard
morphological criteria.
2.2. Mode of Action (MOA) analysis
US EPA (2005) guidelines for cancer risk assessment state that
the MOA should be evaluated in determining the approach for dose
response assessment from positive human or experimental animal
tumor data. This evaluation is accomplished by ﬁrst proposing a
MOA, including identiﬁcation of key events. Data on these key
events, including available in vivo, in vitro, and mechanistic studies
are then evaluated relative to the modiﬁed Hill criteria. When suf-
ﬁcient data are available, a biologically based dose–response
(BBDR) model is the preferred method for low dose extrapolation.
Absent such data, low dose extrapolation usually proceeds via a
linear model (if the chemical acts via a direct DNA-reactive MOA
or the MOA is not known) or a non-linear model (for a non-
DNA-reactive MOA) based on one or more combinations of
relevant tumors. Afterwards, determination of the human equiva-
lent dose from the experimental animal dose is accomplished by
a comparison of human and experimental animal kinetics or a
default procedure.
These guidelines were followed by ﬁrst describing our methods
for analyzing mutagenicity and growth stimulation MOAs. EPA
guidelines (2005) were then followed to model tumors by either
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dose) MOA, or to ‘‘consider the respective contribution of each
mode of action in different dose ranges.’’
The MOA framework within the cancer risk assessment guide-
lines of the US Environmental Protection Agency (2005) is built in
part on the work of Meek et al. (2003). In accordance with these
guidelines, we consider whether each hypothesized MOA is sufﬁ-
ciently supported by the existing human or experimental animal
data, and whether the available evidence suggests these MOAs are
relevant to humans. Based on the data describing the key precursor
events, we also consider life stage susceptibility for dose–response
analysis. Furthermore, as per US EPA (2005) guidelines, the model
used for extrapolation to low doses is determined based on themost
relevant MOA(s) given our current understanding of the science.
US EPA (2005) lists several potential MOAs. We speciﬁcally
investigated two of them discussed by EPA (2013) for the liver
and nasal tumors evoked by oral 1,4-dioxane exposures; these
MOAs were:
 A heritable mutation to liver and/or nasal cell DNA.
 Liver and nasal cytotoxicity followed by regenerative cell prolif-
eration and stimulation of endogenously mutated DNA.
The mutagenicity data was analyzed to determine the extent to
which a mutagenic MOA is responsible for the liver and nasal tu-
mors observed in the 1,4-dioxane bioassays. To make that evalua-
tion, one is interested in the consistency of, or concordance
between, the pattern of tumor response, on the one hand, and
the pattern of the selected genotoxicity measures. This comparison
is ideally done between the tumor data and a marker of mutage-
nicity in the same species, sex, and tissue.
If such mutagenicity data are negative for 1,4-dioxane, then rel-
evant available in vivo genotoxicity data are reviewed for possible
relevance for tumor development. Concordance of the tumor and
genotoxicity patterns is based on comparison of the dose–response
curves describing the observed tumor and genotoxicity data sets.
We also evaluate data to determine the extent to which a regen-
erative cell proliferation mode of action is responsible for the liver
and nasal tumors observed in the bioassays. For this MOA, we used
US EPA Guidelines for Cancer Risk Assessment (2005) and speciﬁ-
cally, the modiﬁed Hill criteria in the determination of sufﬁciency
of evidence.
2.3. Modeling tumors via mutagenic and regenerative cell proliferation
MOAs
The US EPA approach for quantitatively characterizing cancer
risk begins by modeling the available data and deﬁning a Point of
Departure (POD). The POD is a dose–response point that is esti-
mated for a speciﬁed response, the Benchmark Response (BMR),
near the low end of the dose–response data (US EPA, 2005). The
1,4-dioxane analysis focuses on experimental animal data, thus
the approaches described here are those most relevant to animal
studies. Risk levels of 1–10% are commonly used for the BMR,
and the US EPA Guidelines for Cancer Risk Assessment (2005) spec-
ify that the POD should be the lowest POD that is adequately sup-
ported by the data. The dose at the BMR, called the Benchmark
Dose (BMD), is usually deﬁned in terms of extra risk. For a speciﬁed
BMR, the BMD is then the dose that satisﬁes the following formula
for extra risk:
BMR ¼ PðBMDÞ  Pð0Þ
1 Pð0Þ
As per EPA (2005) guidelines, uncertainties were represented in
the estimation of risk as the best estimate and its upper bound. A
lower bound on risk is often desired to show the full range ofuncertainty, but current EPA (2012) BMD software does not pro-
vide a way to estimate this risk in many of its models. For policy
reasons, the POD is usually deﬁned using the upper bound on the
risk, which is associated with the lower 95% conﬁdence bound on
the prescribed dose, referred to as the lower bound on the bench-
mark dose, or BMDL. However, as noted above, US EPA (2005) also
recommends presenting the best estimate POD, referred to as the
Benchmark Dose, or BMD, to improve the uncertainty description.
Another common term is the Slope Factor (SF). This value is calcu-
lated from the BMD or BMDL and represents the slope at the given
parameter; the SF can be used to determine risk at lower doses.
The next step depends on the MOA that has been determined to
apply to the tumor type of interest. For a mutagenic MOA, the
modeling assumption, in the absence of more deﬁnitive data, is a
one molecule-threshold dose, and low-dose linearity. A line con-
nects the POD to the origin, corrected for background. The slope
of the line is used to estimate a risk per incremental increase in
dose. Using a BMD or BMDL based on extra risk, one calculates
the SF directly from the desired BMR level. The stability of the
slope estimate is gauged by evaluating it for different BMR and
BMD values. For example, if the BMD at 0.10 excess risk equals
0.83, then:
SF ¼ BMR=BMD ¼ 0:10=0:83 ¼ 0:0012
When the chemical acts via a regenerative hyperplasia MOA,
which is expected to exhibit a threshold in response, US EPA
describes a nonlinear modeling approach for quantitatively
characterizing cancer risk. In this case, the POD (based on either
tumors or a precursor endpoint) is used to develop a Reference
Dose or Reference Concentration for oral or inhalation exposures,
respectively, following the procedures prescribed by US EPA for
non-cancer toxicity, with the BMDL commonly divided by the
appropriate combination of uncertainty factors (US EPA, 2002).
However, if supporting data exists, US EPA (2005) guidelines
also allow the separate evaluation of MOAs in different parts of
the dose response range. In this case, the guidelines are not pre-
scriptive, but an approach consistent with the guidelines would
be to select a model within US EPA’s array that best ﬁts the most
relevant data from a MOA(s) perspective. Afterwards, different
approaches may be used at points of the dose response curve
associated with the appropriate MOA(s). An example of this latter
approach has been published for acrylamide exposures by Dourson
et al. (2008).
2.4. Maximum contaminant level goal
The maximum contaminant level goal (MCLG) is the level of a
contaminant in drinking water at or below which there is no
known or expected risk to health. The Maximum Contaminant
Level (MCL) is the highest level of a contaminant that is allowed
in drinking water. Typically MCLs are set as close to MCLGs as
feasible taking the best available treatment technology and cost
into consideration. The main difference between the MCLG and
MCL is that the MCLG is a non-enforceable public health goal and
the MCL is an enforceable standard. The ﬁrst step in determining
a MCL is an evaluation of the adverse effects caused by the
chemical and the doses needed to cause such effects.
The MCLG can be derived for chemicals with a cancer endpoint
based on the SF or a non-cancer endpoint based on the RfD. The
MCLG is derived by converting the SF or RfD to a water concentra-
tion. If an RfD is utilized, then EPA (2005) recommends the use of a
margin of safety to protect against adverse effects. This is done by
calculating the daily average intake for humans using the RfD and
adjusting it using the average body weight of 70 kg and a water
consumption of 2 liters/day. The MCL would then be based on this
water concentration and a default assumption that the water is
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relative source contribution (RSC). However, the RSC can be based
on actual data from the various sources of exposure, such as water,
food, air and consumer products. Based on the available data for
1,4-dioxane, a data-derived RSC was considered.
3. Results
3.1. Liver tumors and the re-review of the NCI mouse liver slides
Tables 1 through 5 show the results of the re-review of the liver
slides from mice from the NCI study conducted in 1978. Fig. 2
shows photomicrographs of select lesions observed during the
pathology review of the slides. These results and photomicro-
graphs were summarized in a study report (McConnell, 2013). Le-
sions that were noted with increased incidence included the
following:
 Depletion of hepatocellular glycogen (Table 1): Depletion,
shown here as an average severity score where the lower the
score the more the depletion, was noted in many control mice,
probably due to various causes, e.g., inanition and chronic dis-
ease of various types. Despite this high control incidence,
exposed mice appeared to have a higher depletion of glycogen
in the 1,4-dioxane-exposed mice in a dose–response manner.
 Hepatocellular hypertrophy (Tables 2 and 5): There was a very
clear dose–response for this endpoint, shown here as both an
increase in incidence and average severity score where the
higher the severity score the greater the hypertrophy. In
affected livers, most of the hepatocytes were diffusely enlarged.
In cases with minimal hypertrophy, the affected hepatocytes
were more apparent in the central lobular areas near the central
vein.
 Necrosis (Table 2) (particularly hepatocellular): Dose-related
hepatocellular necrosis was apparent in most of the exposed
animals, manifested as isolated diffusely scattered necrotic
hepatocytes. Most of the necrotic hepatocytes were centrilobu-
lar, particularly near the central veins.
 Inﬂammation (Table 2): Inﬂammation was micro-focal and was
primarily in reaction to the necrosis of individual hepatocytes
(described above). The appearance was somewhat unusual in
that enlarged hepatocytes with almost normal appearing nuclei
appeared to be invaded by neutrophils and lymphocytes. There
was a deﬁnite dose–response.
 Fatty inﬁltration: Fatty change was only rarely observed and
there was no evidence of a treatment related effect (data not
shown).
 Non-neoplastic hyperplasia (e.g., focal hyperplasia of several
types):
 Kupffer cell (Table 2): An increase in Kupffer cell hyperplasia
was found in male mice and high dose female mice, and the
response appeared to be dose related.Table 1
Glycogen incidences in male and female B6C3F1 mice from NCI (1978).
Dose n 2 = Normal
(%)
1 = Decreased/
minimal (%)
0 = No
glycogen (%)
Average
score
Male
Control 44 14 (32) 19 (43) 11 (25) 1.1
Low 43 5 (12) 6 (14) 32 (74) 0.4
High 42 1 (2.4) 6 (14) 35 (83) 0.2
Female
Control 46 8 (17) 20 (44) 18 (39) 0.8
Low 37 7 (19) 13 (35) 17 (46) 0.7
High 30 3 (10) 6 (20) 21 (70) 0.4 Bile Duct Hyperplasia: Bile duct hyperplasia was only found in a
few animals and only in exposed animals (data not shown).
There were not enough affected mice to make any deﬁnite con-
clusions regarding dose-effects for this endpoint.
 Basophilic, eosinophilic, clear cell and mixed cell foci (Table 3):
These speciﬁc types of hyperplastic foci were observed in a
dose-related pattern, especially when the various types of foci
are combined. The incidence of foci decreases at the high dose
as the proportion of experimental animals with adenomas and
carcinomas increases. This suggests that tumors arise from
these foci. However, an alternative explanation might be that
the available area of adjoining normal liver in the tissue sample
that were taken was less due to the tumors, and that if more tis-
sue samples were taken from areas without tumors, more hepa-
tic foci would have been found.5 Interestingly, the hepatocytes in
these clonal expansions are generally of normal size, i.e., not
enlarged (hypertrophic), as are the hepatocytes surrounding the
foci.
 Various types of neoplasms (Table 4), e.g., hepatocellular ade-
noma and carcinoma, leukemia, lymphoma, etc. were observed
with an increased incidence in the treated mice. The tumor inci-
dence closely matched the incidence reported in the NCI study
(1978).
In addition to the increase in incidence in many of these end-
points, the average severity of these endpoints also generally in-
creased as shown in Table 5. In general, the non-neoplastic
lesions in the male mice were more apparent than in the females,
but this may be due to the fact that the low dose female mice had
only about ½ of the dose of the low dose male mice. The high doses
in both sexes gave roughly comparable results, except for the inci-
dence of Kupffer cell hyperplasia.
The appearance of the liver toxicity follows the pattern where
glycogen depletion occurs either concurrently with, or preceding,
hypertrophy in both sexes. This was followed closely by necrosis
and inﬂammation in males, but a high control incidence of necrosis
and inﬂammation clouded this overall pattern found in females.
This female control incidence may have been due to an infection
of murine hepatitis virus that was known to occur in all mice at
the time of the bioassay (as per EEMc).
The incidence of hypertrophy, foci of hepatocyte hyperplasia,
adenoma and carcinoma followed the pattern shown in Fig. 3 for
pooled male and female average responses. In terms of dose–
response behavior, hypertrophy preceded the formation of foci,
which appeared to precede formation of tumors. This pattern
was also evident in an individual animal analysis (data not shown,
but available upon request).3.2. Description of key events in the proposed MOA for liver tumors
Evaluation of genotoxicity studies in the scientiﬁc literature
indicate that 1,4-dioxane does not cause point mutations, DNA re-
pair, or initiation. However, 1,4-dioxane appeared to promote tu-
mors and stimulate DNA synthesis. Using a Mode of Action
(MOA) analysis and human relevance framework (US EPA, 2005),
the weight of the evidence supports a non-linear mode of action
with 1,4-dioxane causing liver tumors in rats and mice through a
MOA involving cytotoxicity followed by regenerative hyperplasia
and stimulation of endogenously formed mutations as the cause5 One approach to make this distinction would be to nominalize the amount of
non-tumor tissue among experimental groups and then express foci per square cm
liver tissue examined (excluding the obvious adenomas and carcinomas). Of course if
a hepatic focus is still present at the end of a 2-year NCI bioassay, it is not a
particularly aggressive lesion and its relationship to becoming a cancer seems highly
unlikely.
Table 2
Incidences of selected nonneoplastic lesions in male and female B6C3F1 mice from NCI (1978).
Dose 0-No lesion (%) 1-Minimal (%) 2-Mild (%) 3-Moderate (%) 4-Marked (%) Total (%)
Male
Hypertrophy
Control (0 mg/kg day) 41 (93) 2 (4.5) 1 (2.3) 0 0 3/44 (6.8)
Low (720 mg/kg day) 2 (4.7) 17 (40) 24 (56) 0 0 41/43 (95)
High (830 mg/kg day) 1 (2.4) 13 (31) 27 (64) 1 (2.4) 0 41/42 (98)
Necrosis
Control (0 mg/kg day) 44 (92) 4 (8.3) 0 0 0 4/48 (8.3)
Low (720 mg/kg day) 4 (9.8) 16 (39) 16 (39) 5 (12) 0 37/41 (90)
High (830 mg/kg day) 7 (18) 20 (50) 10 (25) 3 (7.5) 0 33/40 (83)
Inﬂammation
Control (0 mg/kg day) 44 (92) 4 (8.3) 0 0 0 4/48 (8.3)
Low (720 mg/kg day) 4 (9.8) 17 (41) 16 (39) 4 (9.8) 0 37/41 (90)
High (830 mg/kg day) 8 (20) 19 (48) 10 (25) 3 (7.5) 0 32/40 (80)
Kupffer cell hyper
Control (0 mg/kg day) 41 (93) 2 (4.5) 1 (2.3) 0 0 3/44 (6.8)
Low (720 mg/kg day) 14 (33) 20 (47) 8 (19) 1 (2.3) 0 29/43 (67)
High (830 mg/kg day) 11 (26) 15 (36) 13 (31) 3 (7.1) 0 31/42 (74)
Female
Hypertrophy
Control (0 mg/kg day) 46 (100) 0 0 0 0 0/46 (0)
Low (380 mg/kg day) 20 (54) 14 (38) 3 (8.1) 0 0 17/37 (46)
High (860 mg/kg day) 1 (3.3) 14 (47) 12 (40) 3 (10) 0 29/30 (97)
Necrosis
Control (0 mg/kg day) 19 (41) 25 (54) 2 (4.3) 0 0 27/46 (59)
Low (380 mg/kg day) 20 (54) 14 (38) 2 (5.4) 1 (2.7) 0 17/37 (46)
High (860 mg/kg day) 2 (11) 12 (63) 5 (26) 0 0 17/19 (90)
Inﬂammation
Control (0 mg/kg day) 20 (44) 24 (52) 2 (4.3) 0 0 26/46 (57)
Low (380 mg/kg day) 20 (54) 14 (38) 2 (5.4) 1 (2.7) 0 17/37 (46)
High (860 mg/kg day) 3 (16) 11 (58) 5 (26) 0 0 16/19 (84)
Kupffer cell hyper
Control (0 mg/kg day) 46 (100) 0 0 0 0 0/46 (0)
Low (380 mg/kg day) 36 (97) 1 (2.7) 0 0 0 1/37 (2.7)
High (860 mg/kg day) 21 (70) 5 (17) 2 (6.7) 1 (3.3) 1 (3.3) 9/30 (30)
Table 3
Foci incidences in male and female B6C3F1 mice from NCI (1978); B = basophilic; E = eosinophilic; CC = clear cell; MC = mixed cell.
Dose n B Focus (%) E Focus (%) CC Focus (%) MC Focus (%) Total Foci (%)
Male
Control 44 2 (4.5) 0 2 (4.5) 0 4/44 (9.1)
Low 43 6 (14) 2 (4.7) 2 (4.7) 3 (7.0) 13/43 (30)
High 42 2 (4.8) 0 4 (9.5) 1 (2.4) 7/42 (17)
Female
Control 46 1 (2.7) 1 (2.2) 0 0 1/46 (2.2)
Low 37 1 (3.3) 5 (14) 2 (5.4) 2 (5.4) 10/37 (27)
High 30 2 (6.7) 4 (13) 1 (3.3) 8/30 (27)
Table 4
Incidences of animals with neoplasms in male and female B6C3F1 mice from NCI
(1978); parentheses indicate percentage.a
Dose Adenoma Carcinomas Adenomas/carcinomas
NCI Recount NCI Recount Recount
Male
Control 6/49 2/44 (4.5) 2/49 4/44 (9) 5/44 (11)
Low 1/50 1/48 (2) 18/50 16/48 (33) 17/48 (35)
High 4/47 3/48 (6) 24/47 21/48 (43) 22/48 (45)
Female
Control 0/50 0/49 0/50 0/49 0/49
Low 9/48 7/45 (16) 12/48 7/45 (16) 14/45 (31)
High 6/37 11/37 (30) 29/37 23/37 (62) 29/37 (78)
a In some cases the ‘‘n’’ between foci and tumor counts differ and in some cases the
‘‘n’’ between the tumor counts shown here and with NCI differ. In former case this is
due to the fact that some tissues did not have enough non-tumor related tissue to
make a judgment on foci. In the latter case this is due to the fact that the reread of a
few slides was not possible, or in one case the reread allowed a larger ‘‘n’’.
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to 1,4-dioxane. See Fig. 1. The speciﬁc key events in this mode of
action include: (1) accumulation of parent compound, (2) liver cell
hypertrophy and necrosis, (3) DNA synthesis, (4) regenerative cell
proliferation, and (5) promotion of endogenously-initiated tumors.Table 5
Average severity score in male and female B6C3F1 mice from NCI (1978).
Dose Hypertrophy Necrosis Inﬂammation Kupffer cell hyperplasia
Male
Control 0.1 0.08 0.08 0.1
Low 1.5 1.5 1.5 0.9
High 1.7 1.2 1.2 1.2
Female
Control 0 0.6 0.6 0
Low 0.5 0.6 0.6 0.03
High 1.6 1.2 1.1 0.5
Fig. 2. Photomicrographs from the re-review of the original NCI (1978) study slides.
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Humans, rats, and mice extensively metabolize 1,4-dioxane
(Young et al., 1978; Kociba et al., 1975; Sweeney et al., 2008). Evi-
dence supports the conclusion that cytochrome P450 (CYP450)
oxidases are the major pathway for 1,4-dioxane oxidation,
although the precise CYP450 has not been unequivocally identiﬁed.
In rats, and by inference in humans as well, metabolism is a capac-
ity-limited process (Young et al., 1978). As doses of 1,4-dioxane in-
crease, a transition occurs from linear ﬁrst-order pharmacokinetics
to nonlinear Michaelis–Menten kinetics. This transition appears to
occur at plasma concentrations in the range of 30–100 lg/mL. At
doses yielding plasma concentrations below this level, 1,4-dioxane,
is rapidly and efﬁciently detoxiﬁed. When dose of 1,4-dioxane ap-
proaches or exceeds the metabolizing capacity, the unmetabolized
fraction of the dose increases and target organ toxicity occurs (Koc-
iba et al., 1975; Young et al., 1978). Thus, there appears to be a
threshold below which metabolism and elimination are rapid
and with less or perhaps without toxicological effects. In rat stud-
ies as long as 2 years, administration of 0.01% 1,4-dioxane in drink-
ing water produces plasma levels that are below the saturating
threshold and no discernible effects is observed (Kociba et al.,
1974, 1975). Several studies, including the 1978 NCI study, admin-
istered high doses (0.5% and 1.0% in drinking water) that would be
expected on the basis of 1,4-dioxane’s pharmacokinetic disposition
to yield plasma concentrations well above 100 lg/mL. At thesedoses the parent compound would be eliminated more slowly
and accumulate, resulting in pathology. Likewise, the higher-
end doses used in most chronic and sub-chronic studies (i.e.,
1–2% in drinking water) are well in excess of the metabolizing
capacity and would be expected to result in toxicological mani-
festations (Argus et al., 1965, 1973; Kociba et al., 1974; NCI,
1978). However, Kano et al. (2008) gave numerous doses over
13 weeks in both rats and mice, including several doses that
appeared to be within metabolic capacity, with few if any non-
cancer effects noted.
Human environmental exposures to 1,4-dioxane are unlikely to
approach doses that saturate metabolizing enzymes and which
produce liver and nasal tumors in rats. Saturation of the CYP450
enzymes that metabolize 1,4-dioxane would be predicted to occur
at the high 1,4-dioxane doses used in chronic cancer bioassays,
resulting in elevated urinary and respiratory excretion of the par-
ent compound. Conversely, at the environmentally- and occupa-
tionally-relevant concentration of 50 ppm (which is the ACGIH
threshold limit value for 1,4-dioxane), humans extensively metab-
olize 1,4-dioxane with over 99% metabolism of a 50 ppm/6 h inha-
lation exposure. The elimination half-life in rats exposed to 50 ppm
1,4-dioxane for 6 h was calculated to be 1.01 h (Young et al., 1978).
Hence, since humans, like rats, efﬁciently metabolize 1,4-dioxane
at low doses, enzyme saturation is negligible at low exposure
levels.
Fig. 3. Pooled incidence for 4 effects in B6C3F1 male and female mice given 1,4-dioxane (NCI, 1978).
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Fig. 4. Benchmark dose (BMD) in mg/kg day from log-probit model plot for the hepatic necrosis endpoint with a benchmark response of 10. Results of EPA (2012) modeling
software.
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Liver cell hypertrophy and necrosis are key events in the 1,4-
dioxane MOA leading to regenerative cell proliferation and, with
chronic exposures, liver tumors. Liver changes including
centrilobular swelling, single cell necrosis coincide exclusively
with saturating doses of 1,4-dioxane and occur in as little as
11 weeks (Stott et al., 1981; Kano et al., 2008; Kasai et al., 2008,
2009). The mechanism by which 1,4-dioxane, or its metabolites,
are hepatotoxic has not been rigorously investigated. Hence, it
has been proposed that liver toxicity due to uncharacterized
metabolites cannot be ruled out (US EPA, 2013). However, evidence
suggests this scenario is highly unlikely: (1) phenobarbital-medi-
ated induction of 1,4-dioxane metabolism does not increase liver
toxicity (Nannelli et al., 2005); and (2) pretreatment with inducers
of CYP450 also did not signiﬁcantly change the extent of covalent
binding in subcellular fractions (Woo et al., 1977). The macromol-
ecule(s) to which 1,4-dioxane bound was not identiﬁed, but it is
reasonable to expect that such covalent binding would be related
to 1,4-dioxane toxicity. These data suggest that an unknown,
highly toxic intermediate does not play a role in liver toxicity.
Although there remains a remote possibility that a non-CYP450-
mediated pathway yields a reactive intermediate at high doses,
such an intermediate, if present, would not be a key event in the
formation of tumors at low, environmentally relevant doses. The
pharmacokinetic description of 1,4-dioxane disposition, however,
supports the parent molecule as the toxic entity.
Evidence of hepatocellular damage preceding evidence of hepa-
tocellular tumors caused by higher doses of 1,4-dioxane has been
provided by several studies. Kociba et al. (1971, 1974) reported
hepatocellular degeneration and necrosis in rats receiving 1.0% or
0.1% 1,4-dioxane. In 13 week studies, both Kasai et al. (2008) and
Kano et al. (2008) reported a dose–response increase in plasma
AST and ALT in male and female rats (Kasai et al.) and in both rats
and mice (Kano et al.) with concurrent liver lesions (e.g., single-cell
necrosis and centrilobular swelling). These changes temporally
precede the pre-neoplastic and neoplastic changes characterized
in subsequent 2-year studies (Kasai et al., 2009; Kano et al.,
2009). Similarly, Stott et al. (1981) also reported signs of liver cyto-
toxicity at a dose of 1000 mg/kg/day but not 10 mg/kg/day follow-
ing 11 weeks of 1,4-dioxane exposure.8 See also EPA (2013) page 76, Table 4-23.
9 The publication by King et al. (1973) was a preliminary report with several
signiﬁcant shortcomings. For example, it was reported as an ongoing study. However,
ﬁnal results were never published; drinking water treatment groups were on study
eight weeks longer than the controls to which they were compared; profound
mortality was associated with dermal administration of 1% 1,4-dioxane to rats (the
only concentration tested dermally); there is no control for 1,4-dioxane alone without
initiation. Thus, the King et al. study provides unreliable evidence regarding 1,4-3.2.3. Key event 3: DNA synthesis
EPA (2013) reported that 1,4-dioxane does not cause DNA re-
pair activity in ﬁve standard in vitro and in vivo bioassays that
tested for the presence of DNA repair in various model systems.6
Conversely, 1,4-dioxane does cause DNA replication as evidenced
by in vitro bioassays in rat hepatocytes. Speciﬁcally, three out of ﬁve
studies, all conducted in rats, reported that 1,4-dioxane stimulated
DNA synthesis in hepatocytes at doses at or above 1000 mg/kg. Of
the two remaining studies, one was negative for replication in nasal
epithelial cells (1500 mg/kg day for 2 week) and one was equivocal
(2000 mg/kg).7 Both the negative ﬁndings for DNA repair and the po-
sitive ﬁndings for DNA synthesis are consistent with our proposed
MOA.
In general 1,4-dioxane does not appear to be genotoxic; nor do
DNA and RNA synthesis appear to be genotoxic events. Rather,
DNA synthesis appears to be a key event for a regenerative cell pro-
liferation and/or tumor promotion and can occur in either the
presence or absence of cytotoxicity. In light of the extensive toxi-
cology evoked by 1,4-dioxane in the long-term animal bioassays
(v. infra), DNA synthesis provides evidence that 1,4-dioxane pro-
motes cell proliferation through cytotoxicity.6 See also EPA (2013) Table 4-23 (p. 76).
7 See also EPA (2013) Table 4-24 (pages 79).3.2.4. Key event 4: Regenerative cell proliferation
According to the proposed MOA, regenerative hyperplasia is
anticipated to accompany hepatotoxicity. Dose–response and
temporal data support the occurrence of cell proliferation and
hyperplasia prior to the development of liver tumors in the rat
model. For example, Kociba et al. (1971, 1974) showed evidence
of hepatic regeneration as indicated by hepatocellular hyperplas-
tic nodule formation in rats receiving 1.0% or 0.1% 1,4-dioxane.
Using replicative DNA synthesis as a surrogate marker of cell pro-
liferation, increased hepatocyte proliferation is a common ﬁnding
at tumorigenic doses of 1,4-dioxane (Goldsworthy et al., 1991;
Miyagawa et al., 1999; Stott et al., 1981; Uno et al., 1994). Cell
proliferation appears to be an early response with signiﬁcant
changes (1.5- to 2-fold) occurring in rats with as little as 2 weeks
of exposure (Goldsworthy et al., 1991; Stott et al., 1981). Simi-
larly, tumor promotion studies have shown that 1000 mg/kg
1,4-dioxane promotes formation of GGT-positive liver foci in rats
(Lundberg et al., 1987) and enhances the growth of previously
initiated skin cells in mice (King et al., 1973). Given time, prolif-
erative changes manifest as pre-neoplastic foci in studies where
the histopathology of such changes are reported (Kano et al.,
2008; Lundberg et al., 1987; Kasai et al., 2008). Thus, it is highly
plausible that doses of 1,4-dioxane exceeding the capacity to be
metabolized are linked to the occurrence of liver and respiratory
tumors in rodents. This is further supported by evidence from
Koissi et al. (2012) showing that the oxidation products of
1,4-dioxane do not elicit preneoplastic liver foci in rats when
administered orally for 12 weeks (Koissi et al., 2012).3.2.5. Key event 5: Promotion of endogenously-initiated tumors
Three studies relevant to tumor initiation and promotion estab-
lish that 1,4-dioxane does not cause initiation in standard in vivo
bioassays, in agreement with the absence of observed mutagenic
or genotoxic activity (Bull et al., 1986; King et al., 1973; Lundberg
et al., 1987).8 Although not an initiator, 1,4-dioxane does causes pro-
motion of tumors, as evidenced by positive results in two standard
initiation/promotion bioassays (King et al., 1973; Lundberg et al.,
1987). Both studies have deﬁciencies that limit interpretation, how-
ever.9 Lundberg et al. (1987) evaluated tumor promotion of 1,4-diox-
ane after initiation and partial hepatectomy in terms of signiﬁcant
GGT-positive foci and lipid accumulation only. Following initiation,
statistically increased foci volume was observed in the highest dose
group given 1000 mg/kg. In this dose group signiﬁcantly increased
foci volume was associated with hepatocyte lipid accumulation, an
indicator of liver toxicity. Therefore, toxicity may be an important
component for a signiﬁcant increase in this pre-neoplastic lesion.
The study by King et al. (1973) presented limited data, as it was a
preliminary report of interim results. The complex study design eval-
uated tumor initiation and promotion by oral and dermally adminis-
tered 1,4-dioxane. From the limited data presented, this study
provides evidence that 1,4-dioxane is not a complete carcinogen or
initiating agent; it does support other studies that 1,4-dioxane has
tumor promoting activity. In both studies, tumor promotion wasdioxane as a tumor promoter and no evidence regarding initiation. The primary
limitation of Lundberg et al. (1987) is that it focuses only on GGT-positive liver foci
and lipid accumulation and does not report whether any other pathology was
observed.
Table 6
Kociba et al. (1971, 1974) Rat hepatocellular necrosis data used for BMD analysis.
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either dermal or oral routes (King et al., 1973; Lundberg et al., 1987).Dose (mg/kg day) No. of animals Hepatocellular necrosis incidencea
Male rats
0 60 2
9.6 60 6
94 60 12
1015 60 24
Female rats
0 60 1
19 60 2
148 60 11
1599 60 31
a Incidence data for both sexes was combined for the BMD analysis.3.2.6. Alternative MOA hypothesis
In several respects 1,4-dioxane acts as if it were a mutagenic
carcinogen. It evokes multiple tumors in both sexes of two differ-
ent species, and some of these tumors are malignant. Thus, it is
reasonable to explore a mutagenic MOA for this chemical.
For example, 1,4-dioxane has been tested for genotoxicity using
in vitro assay systems with prokaryotic organisms, non-mamma-
lian eukaryotic organisms, and mammalian cells, both with and
without metabolic activation. Based on the data presented by
EPA (2013), all ﬁfteen mutagenicity tests reported (8 without acti-
vation and 7 with metabolic activation) were negative. In addition,
22 in vitro genotoxicity assays, and 9 in vivo genotoxicity assays
were negative. Eight genotoxicity assays were noted to be positive
but only at high or noted cytotoxic doses. EPA (2013) concluded
that the evidence supports the possibility that 1,4-dioxane is non-
genotoxic or weakly genotoxic. Our conclusion is similar in that
1,4-dioxane does not cause mutations, but differs from EPA
(2013) in that if mutations are caused by 1,4-dioxance, it is only
at high cytotoxic doses. Furthermore, we note that replicative
DNA and RNA synthesis reﬂect cell division, rather than being di-
rect or even indirect measures of DNA damage (unlike reparative
DNA synthesis, which is an indirect measure of DNA damage).
DNA synthesis is a key event for hyperplasia and tumor promotion,
and can occur in either the presence or absence of cytotoxicity. The
DNA synthesis evidence supports the possibility that 1,4-dioxane
promotes cell proliferation, possibly through mitogenesis or
cytotoxicity.
Based on testing results, we conclude that 1,4-dioxane does not
cause mutagenicity as evidenced by uniformly negative results in
standard in vitro and in vivo genotoxicity bioassays at levels that
are not overtly toxic, but it may be a clastogen in vivo, in light of
the mixed results in the micronucleus assays. It follows that muta-
tions needed for tumor formation are then likely from the known
endogenously available pool of mutations, and that a regenerative
hyperplasia evokes more of these endogenous mutations to form
tumors. Mutation potentially caused by 1,4-dioxane at high doses
is precluded as a key event in tumor formation.3.3. Derivation of a drinking water level
3.3.1. Dose–response assessment for key events for liver toxicity/
tumors
EPA (2013) used Kociba et al. (1974) for the development of its
RfD. We agree with EPA in its choice of study and critical effect, but
based our assessment on the laboratory report of this published
study, kindly provided by The Dow Chemical Company (Kociba
et al., 1971), which showed additional quantitative data for the li-
ver and kidney effects. After a review of this laboratory report, we
selected histopathology diagnoses reﬂective of key events in the
process of tumor formation in the liver of Sherman rats for the pur-
poses of benchmark dose (BMD) modeling (Fig. 4). Speciﬁcally,
hepatocellular cytoplasmic vacuolar degeneration occurred ﬁrst
in the dose scale, with hepatocellular necrosis following. The inci-
dence and severity of both lesions was roughly similar between
male and female rats, and thus, we combined these data into a
joint analysis in order to derive more conﬁdent BMD modeling.
However, males had what appeared to be a hormetic effect for
the degeneration, and BMD modeling did not result in any single
model that met EPA’s criterion of p value greater than 0.1.10 The10 EPA’s BMD models assume monotonically increasing responses and are generally
incapable of modeling hormetic effects.combined rat male and female data also failed this modeling crite-
rion for hepatic degeneration. In contrast, data for individual male
and female rats, and joint modeling for hepatocellular necrosis
yielded successful outcomes.
Thus, BMD modeling was conducted for hepatocellular necrosis
for rats as shown in Table 6. Risk assessment experts use the fol-
lowing 5 criteria from EPA (2002, 2012) in BMD model choice:
(1) Models with p-values greater than 0.1,
(2) Models where the visual ﬁt of the data is good, especially in
the range of the BMD,
(3) Models that have the lowest residuals near the range of the
BMD,
(4) Models that have the lowest AIC, and
(5) Models that have the smallest BMD/BMDL ratio.
Table 7 shows results of this modeling. The log-probit model
has a slightly better ﬁt on several criteria and was selected to pro-
vide the point of departure for development of a Reference Dose
(RfD). But actually any of these models would be a good choice
and lead to a similar RfD.
Nasal toxicity was clearly not the critical effect as demonstrated
by EPA (2013). Thus, since any assessment based on liver effects
would clearly be protective of nasal effects and tumors evoked in
both organs appear to have the same regenerative hyperplasia
MOA, we did not further analyze these tumors.
Renal toxicity as evidenced by both incidence and severity was
also evident at these doses and BMD modeling was also conducted
for selected endpoints. However, since these toxicities did not lead
to tumor formation, and were not more sensitive than the liver ef-
fects, this modeling was not selected for further analysis (data not
shown but available upon request).3.3.2. Developing a Reference Dose (RfD)
We ﬁnd that the most appropriate choice of the point of
departure for development of an RfD for 1,4-dioxane is BMDL10
for hepatic necrosis from the joint analysis of males and females
of 20 mg/kg day (human equivalent concentration of 5.2 mg/
kg day). This choice is supported because among chronic rat
studies, Kociba et al. (1971, 1974) quantiﬁes early events in the
formation of liver tumors (Table 8). Moreover, the choice of rat
versus mouse specie is reasonable because the administered doses
to mice are higher (compare Tables 8 and 9), and this difference is
maintained even after adjustment for the human equivalent
concentration. Finally, the choice of this endpoint is protective,
since liver toxicity, resulting in liver tumors, is the clear apical
effect of greatest intensity in the available array of toxic effects.
This key event is considered to have a threshold as suggested by
the MOA analysis shown in this text.
It would be most appropriate to apply a Chemical Speciﬁc
Adjustment Factor to this adjusted BMDL10 of 5.2 mg/kg day for
Table 7
Selected BMD modeling results from sherman rats in Kociba et al. (1971).
Model BMD mg/kg day BMDL mg/kg day p-value (>0.1) Scaled residualb Visual ﬁta AIC BMD/BMDL ratio
Gamma 48 17 0.41 1.5 Good 376 2.9
LogLogistic 50 19 0.38 1.4 Good 376 2.5
LogProbit 49 20 0.33 1.3 Good 376 2.4
Weibull 49 18 0.40 1.5 Good 376 2.7
a Visual ﬁt rating is classiﬁed as poor, moderate or good.
b Scaled residue near the range of the BMD is selected.
Table 8
Dose response, temporality concordance table for dioxane-induced liver tumors in rats.
Temporala
Dose mg/kg day (Author
reported dose)
Key event 1 Key event 2 Key event
3
Key event 4 Liver adenomas/
carcinomas
Non-linear
metabolism
Hypertrophy Necrosis DNA
synthesis
Hyperplasia/pre-
neoplastic foci
Hours to days Weeks Weeks Weeks Months Years
Stott et al. (1981)b
(11 weeks; oral)
10 nd     
1000 nd + + +  
Kano et al. (2008)c
(13 weeks; oral)
52 (m)/83 (f) (640 ppm) nd   nd  
126 (m)/185 (f) (1600 ppm) nd +(m)/(f)  nd  
274 (m)/427 (f) (4000 ppm) nd +(m)/(f)  nd  
657 (m)/756 (f)
(10000 ppm)
nd + – nd  
1554 (m)/1614 (f)
(25000 ppm)
nd + +d nd  
Kasai et al. (2008)e (13 week;
Inhalation)
584 (800 ppm) nd nd  nd  
1168 (1600 ppm) nd nd  nd  
2336 (3200 ppm)f nd nd + nd +g 
Kano et al. (2009)h (2 year;
oral)
11 (m)/18 (f) (200 ppm) nd nd nd nd  
55 (m)/83 (f) (1000 ppm) nd nd nd nd +(m)/(f) 
274 (m)/429 (f) (5000 ppm) nd nd nd nd + +
Kociba et al. (1974)i (2 year;
oral)
9.6 (m)/19 (f) (0.01%)  nd  nd  
94 (m)/148 (f) (0.1%) +j nd +k nd + 
1015 (m)/1599/1078 (f)
(1%)
+k nd + nd + +
Kasai et al. (2009)l (2 year;
inhalation)
36 (50 ppm) ndm nd  nd  
181 (250 ppm) nd nd  nd  
909 (1250 ppm) nd nd + nd + +
NCI, 1978n (2 year; oral) 240 (m)/350 (f) nd   nd (m)/+(f)o (m)/+p(f)
550 (m)/640 (f) nd   nd +o (m)/+p(f)
a Abbreviations and symbols: +, key event observed; , key event not present;+/, equivocal; nd, not determined/reported.
b Sprague-Dawley rats were dosed daily for 11 weeks (7 days/week) via drinking water with 10 or 1000 mg dioxane/kg body weight.
c Fifty male and female ﬁsher 344 rats were administered 1,4-dioxane in drinking water for 13 weeks.
d Statistically signiﬁcant (p 6 0.01) single cell necrosis, which was consistent with increased plasma AST/ALT levels (male rats) and AST (females). The most sensitive sign of
toxicity was centrilobular swelling of hepatocytes in male rats given 1,600 ppm for 13 weeks. No foci were observed at any dose levels.
e Thirteen-week inhalation of 1,4-dioxane in male and female F344 rats vapor for 6 h/day and 5 days/week. Inhalation exposures were mg/kg doses assuming a minute
volume as 561 ml/min/kg body weight for rats and an uptake ratio of 1,4-dioxane of 100%. Authors included dose groups ranging from 3200 to 100 ppm with doubling
dilutions, but since these groups were negative for the occurrence of key events they have not been included in the table.
f A 6400-ppmexposure was also tested but is not relevant to this mode of action analysis because all animals in this group died at the ﬁrst week of the 13-week exposure
period.
g GST-P-positive liver foci were observed in 3/10 males exposed to 3200-ppm; 2/10 females exposed to 3200-ppm; and 4/10 females exposed to 1600-ppm; no GST-P-
positive foci could be found in any of the 800- and 1600-ppm-exposed males and 800-ppm-exposed females and control groups of both sexes.
h 1,4-dioxane was administered in drinking-water to F344/DuCrj rats (50 of each sex/treatment group) for 2 years.
i Sixty male and female Sherman strain rats,6-8 weeks old, were administered 1,4-dioxane in their drinking water for up to 716 days. Female rats during days 114–198
consumed a dose of 1,4-dioxane ranging from 914–1229 mg/kg/day, but consumed less (1019–1176 mg/kg/day) days 446–460. Male rats receiving the 1% exposure has
similar consumption during the same exposure periods.
j Kociba et al. (1975) 1,4-dioxane: correlation of the results of chronic ingestion and inhalation studies with its dose-dependent fate in rats. In proceedings of the 6th
Annual Conference on Environmental Toxicology (pp. 345–354). Wright-Patterson Air Force Base, OH: Wright-Patterson Air Force Base, Air Force Systems Command,
Aerospace Medical Division, Aerospace Medical Research Laboratory.
k Kociba et al. (1974) reported that the occurrence of hepatocellular degeneration and necrosis, as well as hyperplastic nodule formation, are signiﬁcantly increased by
doses of 1,4-dioxaneP 0.1%; the incidence for these changes are provided in Kociba et al. (1971).
l 2 year inhalation exposure of male ﬁsher 344 rats (50 animals per dose group). Internal exposure from 6-h inhalation exposure was approximated by the authors
assuming the minute volume as 561 ml/min/kg body weight for rats and an uptake ratio of 1,4-dioxane of 100%.
m Kasai et al. (2008) demonstrate steady-state proportionality between dose and plasma blood levels for the top 4 exposure levels (P400 ppm). Based on the pharma-
cokinetics of 1,4-dioxane, these plasma concentrations are predicted to be associated with saturation-limited metabolism.
n Groups of 35 rats of each sex administered 1,4-dioxane at concentrations of either 0.5% or 1.0% (v/v) in the drinking water for 110 weeks.
o Hyperplasia in female rat liver was 7/31 (23%), 11/33 (33%) and 17/53% (53%) for the control, low- and high-dose groups, respectively. In male rats the incidents were 5/31
(16%), 3/32 (9%) and 11/33 (33%) for control, low- and high-dose groups, respectively.
p Adenoma only in female rats and no tumors in male rats.
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Table 9
Dose response, temporality concordance table for dioxane-induced liver tumors in mice.
Temporala
Dose mg/kg day (Author
reported dose)
Key event 1 Key event 2 Key event
3
Key event 4 Liver adenomas/
carcinomas
Non-linear
metabolism
Hypertrophy Necrosis DNA
synthesis
Hyperplasia/pre-
neoplastic foci
Hours to days Weeks Weeks Weeks Months Years
Kano et al. (2008)b
(13 weeks; oral)
86 (m)/170 (f) (640 ppm) nd   nd  
213 (m)/387 (f) (1600 ppm) nd   nd  
585 (m)/898 (f) (4000 ppm) nd +c +d nd  
882 (m)/1620 (f)
(10000 ppm)
nd + + nd  
1570 (m)/2669 (f)
(25000 ppm)
nd + + nd  
Kano et al. (2009)e
(2 year; oral)
49 (m)/66 (f) (500 ppm) nd nd nd nd ndf (m)/+(f)
191 (m)/287 (f) (2000 ppm) nd nd nd nd nd +f
677 (m)/964 (f) (8000 ppm) nd nd nd nd nd +
NCI, 1978 re-read (2 year;
oral)g
380 (f) nd + ±h nd + +
720i (m) nd + + nd + +
830 (m)/860 (f) nd + + nd + +
a Abbreviations and symbols: +, key event observed; , key event not present; ±, equivocal; nd, not determined or reported; m, male only; .f, female only.
b Four-week-old Crj:BDF1 mice of both sexes (n = 60, 10 animals per control or treatment group) were administered 1,4-dioxane in drinking water for 13 weeks.
c Mouse hepatic lesions were characterized by both single cell necrosis and centrilobular swelling of hepatocytes occurring at 4,000 ppm and above.
d Hepatocellular damage indicated by increases in plasma levels of aspartate aminotransferase (AST) and alanine aminotransferase (ALT) were noted in male and female
mice dose with 25,000 ppm dioxane, and ALT was increased in female mice at 10,000 ppm.
e 1,4-dioxane was administered to 50 Crj:BDF1 mice of each sex in the drinking-water for 2 years.
f Hepatic hyperplasia of mice diagnosed in the previous report Yamazaki et al. (1994) was re-examined histopathologically and changed to hepatocellular adenomas and
altered hepatocellular foci.
g McConnell (2013). Review of liver slides from the National Cancer Institute’s bioassay of 1,4-dioxane for possible carcinogenicity conducted in 1978 (NCI, 1978). Groups of
50 mice of each sex administered 1,4-dioxane at concentrations of either 0.5% or 1.0% (v/v) in the drinking water for 90 weeks.
h The occurrence of necrosis in low-dose female mice was equivocal with an incidence similar to the elevated control level but with increased severity of centrilobular
necrosis. Both incidence and severity were increased at the high-dose (Tables 2 and 5 of this text).
i It is noteworthy that the dose of 1,4-dioxane consumed by the high and low doses males in the 1978 NCI study was similar and in the words of the authors, ‘‘did not
reﬂect the 2-fold difference in concentration between the low and high doses’’. Thus, histologic pathology between the low and high males is generally similarity.
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factors exist (IPCS, 2005). Unfortunately, the available comparative
toxicodynamic data between experimental animals and humans,
and comparative toxicokinetic and toxicodynamic data within hu-
mans, are limited and do not allow the development of these pre-
ferred factors. Thus, a default value of 3-fold was used for the
toxicodynamic extrapolation of experimental animals to humans,
and a factor of 10-fold was used for within human variability. An
additional 3-fold factor was used for the lack of a 2-generation
reproductive study, based on EPA (2002) guidelines and prior anal-
ysis of this area of uncertainty by Dourson et al. (1992). This latter
factor addresses the general lack of toxicity data on 1,4-dioxane for
various lifestages, especially in younger experimental animals. The
composite factor is thus 100-fold (i.e., 3  10  3 = 100).11 The use
of this composite factor is similar to that described by EPA (2013),
and for similar reasons.
The resulting RfD is 0.05 mg/kg day. This RfD is similar to that
derived by ATSDR (2007), and for similar reasons.
3.3.3. Maximum contaminant level goal (MCLG)
The Relative Source Contribution (RSC) for 1,4-dioxane is de-
rived by application of the Exposure Decision Tree approach pub-
lished in US EPA’s Methodology for Deriving Ambient Water
Quality Criteria for the Protection of Human Health (US EPA,
2000). The purpose of the RSC is to account for identiﬁed sources
and routes of non-occupational exposures to a particular chemical
and to apportion allowable amounts from each source so that an
individual would not have a total (aggregate) exposure greater
than the RfD. RSCs are calculated for chemicals that are non-carcin-
ogens or threshold carcinogens. Exposure data for various path-
ways are available for 1,4-dioxane.11 As per convention, 3-fold factors are considered as ½ of the default value of 10-
fold; thus multiplying two 3-fold factors is equivalent to a value of 10-fold.Exposures to 1,4-dioxane are expected to be local and limited.
The relevant potential exposure sources are identiﬁed as consumer
products, groundwater, and air. Potential pathways include inges-
tion of water; dermal contact with consumer products, water used
in bathing, and inhaled air. Exposure data (Sapphire Group, 2007)
was evaluated for each of these pathways to determine the RSC
for groundwater. Although the data found in Table 10 are only a
snapshot, they suggest that contributions from water are only
around 10%. In such situations, it is common to use the default va-
lue of 20% for the RSC. Thus, based on the data available data, we
use the default RSC of 20%.
Based on the proposed RfD of 0.05 mg/kg day and applying a
RSC of 20%, the MCLG would be 0.35 mg/L (0.05 mg/kg day
 70 kg  2 L of water per day = 0.35 mg/L or 350 lg/L).
4. Discussion
In making decisions about potential MOA, the animal tumor
ﬁndings often give important clues. Some of the factors EPA
(2005) recommends in a review of such ﬁndings include tumor
types, number of studies and of tumor sites, similarity of metabolic
activation and detoxiﬁcation, inﬂuence of route of exposure on the
spectrum of tumors, effect of high dose exposures on the target or-
gan or systemic toxicity that may not reﬂect typical physiological
conditions, presence of proliferative lesions, effect of dose and time
on the progression of lesions, ratio of malignant to benign tumors
as a function of dose and time, time of appearance of tumors,
development of tumors, tumors at organ sites with high or low
background historical incidence, biomarkers in tumor cells, and
shape of the dose–response curve in the range of tumor
observation.
In considering these criteria, 1,4-dioxane oral exposure appears
to be a mutagenic carcinogen in some respects. It evokes multisite
and multispecies tumors that are not restricted to one sex
Table 10
Sources of 1,4-dioxane from the environment.
Exposure pathway Estimated intakes Average intake mg/kg day RSC%
Sapphire Group (2007) Health Canada (2010)
Ambient air (mg/m3) Median value: 0.00026 Max: 0.000646 0.00013 7.3
Indoor air (mg/m3) Median value: 0.00024 Max: 0.00085 0.00012 6.8
Drinking water (mg/L) Average:0.002 Det limit:0.01 0.00017 9.7
Food (mg/kg food) 0.0012 Det. Limit: 0.002 0.00003 1.5
Dermal (mg/kg bw-day) 0.00019 Absorbed: 0.000061 0.00013 7.1
Consumer products (mg/kg bw-day) 100% absorption: 0.0012 0.00120 68
M. Dourson et al. / Regulatory Toxicology and Pharmacology 68 (2014) 387–401 399suggesting an inﬂuence that is not restricted to gender, strain, or
species. In addition, tumors evoked by 1,4-dioxane are both benign
and malignant. For example, statistically signiﬁcant peritoneal
mesotheliomas are found in male, but not female, F344 rats at high
dose. This sex difference is likely due to the occurrence of tunica
vaginalis mesotheliomas (TVM), a commonly occurring tumor in
these male rats, which grow into the peritoneal cavity. A previous
analyses of such tumors evoked by other chemicals might be help-
ful in understanding the underlying MOA for this tumor caused by
1,4-dioxane. Such an analysis has been done by Haber et al. (2009)
for acrylamide. These investigators explored several MOAs, and
perhaps more importantly, show that the risk calculated from
the observed response in rats is at large variance with the observed
incidence of this tumor in humans. In brief, the quantitative differ-
ence between male rats and male humans is expected to be in the
range of 100- to 1000-fold where humans are less sensitive (Haber
et al., 2009). While TVMs from exposures to 1,4-dioxane and acryl-
amide may be evoked by different MOAs, it is not scientiﬁcally rea-
sonable to assume that such tumors in rats are relevant to humans
based on this quantitative disparity as described by Haber et al.
(2009) without further support.
Statistically signiﬁcant mammary tumors are also found in both
sexes of rats. These tumors are of high dose and uniformly benign.
EPA (2005) considers the evaluation of such uniformly benign tu-
mors on a case-by-case approach. In the case of 1,4-dioxane, nei-
ther the mammary tumors nor peritoneal tumors occur with the
frequency and severity of the liver tumors, nor do dose response
assessments based on these tumors, have the same impact as
assessments based on liver tumors (US EPA, 2013). Therefore, it
does not appear to be scientiﬁcally reasonable to base a dose re-
sponse assessment on this mammary endpoint either. A separate
MOA analysis might be done to further support this, or other
conclusion.
As brieﬂy described earlier, 1,4-dioxane from oral exposures
also causes nasal toxicity as evidenced by histology at all time
points and in a dose related manner in both sexes of rats and mice
as nicely summarized by EPA (2013).12 This toxicity also precedes
tumors in time in both sexes of rats and mice, and also precedes tu-
mors in dose in both sexes of rats and mice.13 The MOA for the devel-
opment of nasal tumors has the same appearance as that for liver
tumors, although the nasal tumor response, like the response for
both TVM and mammary tumors, is not as severe as that for liver.
In contrast to some data that suggest 1,4-dioxane as a muta-
genic carcinogen, all but one of the tumor types (for nasal tumors)
are at sites with a high historical background incidence. In addi-
tion, extensive toxicity is seen in the primary tumors sites (liver
and nose) suggesting a growth-promoting, and speciﬁcally, a
regenerative cell proliferation, mode of action. This latter MOA is12 See EPA (2013) Table 4-2 (p. 34), Table 4-8 (p. 47), Table 4-9 (p. 48), Table 4-12 (p.
52), and Table 4-13 (p. 52), Table 4-17 (p. 59), and Table 4-22 (p. 69).
13 Compare EPA (2013) Table 4-5 (p. 41) and NCI (1978) Tables C1 & C2, (pages 61 &
65) to EPA (2013) Table 4-6 (p. 42). Also compare EPA Tables 4-8 & 4-9 (p. 47-48) to
EPA Tables 4-10 & 4-11 (p. 50). Also compare EPA Table 4-20 (p. 64) to EPA Table 4-21
(p. 65).supported by positive ﬁndings in promotion bioassays and DNA
replication bioassays, and is also supported by the negative ﬁnd-
ings in mutagenicity bioassays, initiation bioassays, and DNA re-
pair bioassays. The modiﬁed Hill criteria of EPA (2005) for the
our proposed regenerative cell proliferation MOA hypothesis for li-
ver tumors was evaluated and determined to be met for strength,
consistency, biological plausibility, and coherence. Moreover, dose
response and temporal concordance for noncancer precursors to
tumors were clearly evident in the reread of the NCI (1978) mouse
liver slides that utilized current histopathology reporting practices.
Our histopathology ﬁndings from the reread of the slides of the
NCI study (1978) are supported by changes in liver enzymes in
mice as shown in (Table 9),14 and by a repeated exposure study of
13 weeks (Kano et al., 2008), where the earliest histopathology key
event in the MOA was single cell liver necrosis and centrilobular
swelling at 4000 ppm and higher doses. Also, altered hepatocellular
foci stained positive with the anti-GST-P antibody were observed in
this 13-week study at the highest exposure dose. While the non-
neoplastic lesions found in the NCI (1978) slide reread that we show
in this paper were not reported in mice from one long-term study
(Kano et al., 2009), the same Japanese investigators did report hepa-
tic hyperplasia (later changed to altered hepatocellular foci) in an
earlier report of this same 2-year study (Yamazaki et al., 1994).
Moreover, mice in the Kano et al. (2009) study showed hepatocellu-
lar injury as evidenced by an enhanced cytolytic release of liver
enzymes (e.g., GOT, GPT, LDH, and ALP) at doses of about
140–1400 mg/kg day [unpublished results].
Based on the current ﬁndings from the comprehensive reread of
the NCI study (with support from other repeated exposure studies
on 1,4-dioxane), the two principal modiﬁed Hill criteria of EPA
(2005), that of temporal and dose concordance, are met in that
chronic bioassays show liver toxicity preceding the development
of tumors in both dose and time for both rats and mice (Tables 8
and 9). The additional modiﬁed Hill criteria for strength, consis-
tency, biological plausibility and coherence are also met. Only
the criterion of speciﬁcity of association is not met. This is because
a regenerative hyperplasia is a common MOA for chemicals
causing tumors.
As to other tumors, peritoneal mesotheliomas, which are only
found in F344 male rats, are not unexpected, but as discussed by
Haber et al. (2009), this tumor endpoint does not have relevance
to humans quantitatively. We therefore did not use this tumor in
a quantitative evaluation of risk to humans. Mammary tumors
are also found in both sexes of rats from oral exposure, but these
tumors are at high dose and uniformly benign. Using EPA (2005)
we judge that a dose response assessment based on these mam-
mary tumors should not be conducted using linear extrapolation
and that a nonlinear assessment based on this endpoint will not
be lower than the calculated RfD for liver toxicity, so that any risk
from this endpoint is prevented. However, a full MOA assessment
of these mesotheliomas and benign mammary tumors might be a
useful exercise for future evaluations.14 See also EPA (2013) Table 4-25 (p. 85).
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Using a Mode of Action (MOA) analysis and human relevance
framework (US EPA, 2005), the weight of the evidence supports a
non-linear mode of action with 1,4-dioxane causing liver tumors
in rats and mice through a MOA involving cytotoxicity followed
by regenerative hyperplasia and the promotion of endogenous
mutations and resulting in increased tumors. This mode of action
appears to also be occurring for tumors in the nasal cavity of ro-
dents exposed to 1,4-dioxane. The speciﬁc key events in this mode
of action include: (1) accumulation of parent compound, (2) liver
cell hypertrophy and necrosis, (3) DNA synthesis, (4) regenerative
cell proliferation, and (5) promotion of endogenously-initiated
tumors.
Evidence for this sequence includes both temporal and dose
concordance through the integration of studies across different
durations and the incorporation of new information from the re-
read of the NCI (1978) mouse liver slides. This reread supports
the view that clearly identiﬁable dose-related non-neoplastic
changes exist in the liver of mice exposed to 1,4-dioxane; speciﬁ-
cally, a dose-related effect in the hypertrophic response of hepato-
cytes, followed by necrosis, inﬂammation and hyperplastic
hepatocellular foci. As per EPA (2005) guidelines, ‘‘a nonlinear
approach should be selected when there are sufﬁcient data to
ascertain the MOA and conclude that it is not linear at low doses
and the agent does not demonstrate mutagenic or other activity
consistent with linearity at low doses.’’ We conclude that the
available data for 1,4-dioxane, and speciﬁcally for its liver
effects, necessitates such a selection. The RfD developed from the
key event of liver necrosis for the liver tumor endpoint is
0.05 mg/kg day. An MCLG developed from this RfD is 0.35 mg/L.Conﬂict of interest statement and Acknowledgments
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